Stock listing
ASX:PTX Prescient Therapeutics Limited Share Price
Follow Prescient Therapeutics Limited into a list and get an email when it puts out news.
Share price · ASX:PTX
$0.055 AUD 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.055 – $0.057 AUDNov 20, 2026
- Volume
- 259,599 sharesNov 20, 2026
- Market cap
- $62.91M AUDAt the close on Nov 20, 2026 · price × 1.14B shares outstanding
- 52-week range
- $0.049 – $0.125 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $52,779 AUDMedian day 514,962 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:PTX · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.055 | 0.000 | 0.0% | $0.057 | $0.057 | $0.055 | 259,599 | |
| $0.055 | -0.002 | -3.5% | $0.056 | $0.057 | $0.055 | 81,081 | |
| $0.057 | +0.001 | +1.8% | $0.056 | $0.057 | $0.055 | 420,330 | |
| $0.056 | -0.002 | -3.4% | $0.058 | $0.060 | $0.056 | 303,956 | |
| $0.058 | -0.005 | -7.9% | $0.063 | $0.063 | $0.058 | 112,889 | |
| $0.063 | +0.001 | +1.6% | $0.064 | $0.065 | $0.063 | 1,237,419 | |
| $0.062 | +0.002 | +3.3% | $0.060 | $0.063 | $0.060 | 575,214 | |
| $0.060 | +0.004 | +7.1% | $0.056 | $0.061 | $0.056 | 397,216 | |
| $0.056 | +0.002 | +3.7% | $0.055 | $0.056 | $0.055 | 264,067 | |
| $0.054 | +0.001 | +1.9% | $0.054 | $0.055 | $0.054 | 266,748 | |
| $0.053 | +0.002 | +3.9% | $0.051 | $0.053 | $0.051 | 149,755 | |
| $0.051 | -0.002 | -3.8% | $0.054 | $0.054 | $0.051 | 141,578 | |
| $0.053 | +0.003 | +6.0% | $0.051 | $0.053 | $0.051 | 49,214 | |
| $0.050 | -0.003 | -5.7% | $0.052 | $0.052 | $0.050 | 240,332 | |
| $0.053 | -0.002 | -3.6% | $0.055 | $0.055 | $0.053 | 191,792 | |
| $0.055 | +0.003 | +5.8% | $0.052 | $0.055 | $0.052 | 17,580 | |
| $0.052 | -0.002 | -3.7% | $0.056 | $0.056 | $0.052 | 457,731 | |
| $0.054 | +0.003 | +5.9% | $0.053 | $0.054 | $0.052 | 271,970 | |
| $0.051 | -0.003 | -5.6% | $0.054 | $0.054 | $0.050 | 1,589,874 | |
| $0.054 | -0.002 | -3.6% | $0.053 | $0.055 | $0.052 | 886,759 | |
| $0.056 | -0.001 | -1.8% | $0.061 | $0.061 | $0.056 | 312,032 | |
| $0.057 | -0.001 | -1.7% | $0.061 | $0.061 | $0.057 | 439,461 | |
| $0.058 | +0.003 | +5.5% | $0.056 | $0.061 | $0.056 | 189,701 | |
| $0.055 | -0.003 | -5.2% | $0.057 | $0.057 | $0.054 | 350,151 | |
| $0.058 | -0.003 | -4.9% | $0.061 | $0.061 | $0.056 | 1,086,998 | |
| $0.061 | -0.004 | -6.2% | $0.066 | $0.066 | $0.061 | 1,116,075 | |
| $0.065 | 0.000 | 0.0% | $0.064 | $0.066 | $0.064 | 350,979 | |
| $0.065 | +0.001 | +1.6% | $0.065 | $0.065 | $0.064 | 233,555 | |
| $0.064 | -0.002 | -3.0% | $0.065 | $0.065 | $0.064 | 32,637 | |
| $0.066 | 0.000 | 0.0% | $0.066 | $0.066 | $0.064 | 736,346 | |
| $0.066 | +0.001 | +1.5% | $0.065 | $0.066 | $0.064 | 501,512 | |
| $0.065 | 0.000 | 0.0% | $0.065 | $0.065 | $0.065 | 536,706 | |
| $0.065 | +0.001 | +1.6% | $0.065 | $0.065 | $0.064 | 489,319 | |
| $0.064 | -0.002 | -3.0% | $0.066 | $0.066 | $0.064 | 245,972 | |
| $0.066 | 0.000 | 0.0% | $0.064 | $0.066 | $0.064 | 1,346,125 | |
| $0.066 | -0.001 | -1.5% | $0.067 | $0.067 | $0.063 | 3,110,713 | |
| $0.067 | -0.005 | -6.9% | $0.073 | $0.073 | $0.067 | 1,574,217 | |
| $0.072 | +0.002 | +2.9% | $0.072 | $0.073 | $0.071 | 1,242,329 | |
| $0.070 | +0.002 | +2.9% | $0.068 | $0.072 | $0.068 | 532,870 | |
| $0.068 | +0.001 | +1.5% | $0.066 | $0.068 | $0.066 | 101,735 | |
| $0.067 | 0.000 | 0.0% | $0.067 | $0.067 | $0.065 | 291,715 | |
| $0.067 | -0.001 | -1.5% | $0.068 | $0.068 | $0.065 | 1,680,441 | |
| $0.068 | 0.000 | 0.0% | $0.068 | $0.068 | $0.068 | 0 | |
| $0.068 | 0.000 | 0.0% | $0.068 | $0.068 | $0.068 | 0 | |
| $0.068 | +0.001 | +1.5% | $0.067 | $0.073 | $0.067 | 3,477,311 | |
| $0.067 | 0.000 | 0.0% | $0.067 | $0.068 | $0.067 | 302,958 | |
| $0.067 | +0.001 | +1.5% | $0.067 | $0.068 | $0.066 | 598,310 | |
| $0.066 | +0.001 | +1.5% | $0.065 | $0.069 | $0.065 | 1,309,998 | |
| $0.065 | -0.003 | -4.4% | $0.068 | $0.069 | $0.065 | 1,367,985 | |
| $0.068 | +0.003 | +4.6% | $0.066 | $0.069 | $0.066 | 1,522,426 | |
| $0.065 | 0.000 | 0.0% | $0.067 | $0.068 | $0.064 | 1,584,896 | |
| $0.065 | 0.000 | 0.0% | $0.067 | $0.069 | $0.065 | 1,297,488 | |
| $0.065 | -0.003 | -4.4% | $0.070 | $0.070 | $0.065 | 1,080,892 | |
| $0.068 | 0.000 | 0.0% | $0.068 | $0.071 | $0.068 | 2,980,678 | |
| $0.068 | +0.001 | +1.5% | $0.068 | $0.069 | $0.067 | 528,412 | |
| $0.067 | -0.001 | -1.5% | $0.068 | $0.068 | $0.066 | 314,819 | |
| $0.068 | 0.000 | 0.0% | $0.068 | $0.068 | $0.067 | 832,037 | |
| $0.068 | +0.002 | +3.0% | $0.067 | $0.068 | $0.066 | 499,072 | |
| $0.066 | -0.001 | -1.5% | $0.067 | $0.067 | $0.064 | 1,296,592 | |
| $0.067 | -0.001 | -1.5% | $0.067 | $0.068 | $0.066 | 681,432 | |
| $0.068 | +0.001 | +1.5% | $0.068 | $0.068 | $0.067 | 840,397 | |
| $0.067 | 0.000 | 0.0% | $0.067 | $0.068 | $0.066 | 1,121,624 | |
| $0.067 | -0.005 | -6.9% | $0.069 | $0.069 | $0.065 | 3,559,404 | |
| $0.072 | -0.004 | -5.3% | $0.077 | $0.077 | $0.071 | 894,856 | |
| $0.076 | -0.001 | -1.3% | $0.076 | $0.080 | $0.075 | 599,958 | |
| $0.077 | -0.002 | -2.5% | $0.080 | $0.080 | $0.075 | 2,246,217 |
Splits
7 splits since 1996 · ASX:PTX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 56-for-55 | Split | |
| 40-for-39 | Split | |
| 1-for-20 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1.0268-for-1 | Split | |
| 20-for-19 | Split | |
| 1-for-2 | Consolidation |
- Ticker
- ASX:PTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 11, 2026
Prescient receives $3.4 million R&D Tax Refund
Latest deck · Oct 14, 2026
Shareholder Meeting (October 2026)
Shareholder meeting · 19 slides
Latest news
Prescient receives $3.4 million R&D Tax Refund
Nov 11, 2026
Closed $0.063 (+1.6%) on Nov 12, 2026
Notification of cessation of securities - PTX
Nov 8, 2026
Closed $0.056 (+3.7%) on Nov 9, 2026
Change of Company Secretary
Oct 22, 2026
Closed $0.054 (-3.6%) on Oct 23, 2026
Results of Annual General Meeting
Oct 14, 2026
Closed $0.061 (-6.2%) on Oct 15, 2026
Chair Address and CEO AGM Presentation
Oct 13, 2026
Closed $0.065 (0.0%) on Oct 14, 2026
September 2026 Quarterly Update and Appendix 4C
Oct 12, 2026
Closed $0.065 (+1.6%) on Oct 13, 2026
Change of Director's Interest Notice
Oct 5, 2026
Closed $0.065 (+1.6%) on Oct 6, 2026
Notification regarding unquoted securities - PTX
Sep 29, 2026
Closed $0.067 (-6.9%) on Sep 30, 2026
Section 708A Cleansing Notice
Sep 29, 2026
Closed $0.067 (-6.9%) on Sep 30, 2026
Application for quotation of securities - PTX
Sep 29, 2026
Closed $0.067 (-6.9%) on Sep 30, 2026
Prescient Therapeutics Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 34 in the last 12 months · 249 in all · newest Nov 11, 2026 · oldest 2016
- Decks
- 45 decks · latest Oct 14, 2026
Valuation
Price/book 4.4× against a median of 3.0×: 6th lowest of 9 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $54.09M AUD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Prescient Therapeutics Limited · ASX:PTX | US$41.64M | US$35.80M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP | US$42.45M | −US$68.98M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 1.85 |
| Arecor Therapeutics PLC · LSE:AREC | US$42.37M | US$38.32M | 48.8× | 17.1× | n/a | 8.8× | 38.7% | 0.0× | n/a |
| OS Therapies Incorporated · AMEX:OSTX | US$42.00M | US$41.57M | n/a | n/a | n/a | n/a | n/a | n/a | 1.70 |
| Advagene Biopharma Co., Ltd. · TPEX:6709 | US$41.88M | US$32.02M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| Biomea Fusion, Inc. · NASDAQ:BMEA | US$41.75M | US$15.85M | n/a | n/a | n/a | 5.5× | n/a | 0.1× | 1.14 |
| Mereo BioPharma Group plc · NASDAQ:MREO | US$41.52M | US$16.00M | n/a | 20.0× | n/a | 1.8× | n/a | 0.0× | 1.34 |
| Elicio Therapeutics, Inc. · NASDAQ:ELTX | US$41.05M | US$19.78M | n/a | n/a | n/a | 2.2× | n/a | 0.5× | 1.81 |
| MiNK Therapeutics, Inc. · NASDAQ:INKT | US$40.93M | US$33.46M | n/a | 167× | n/a | n/a | n/a | n/a | 0.81 |
| Median of the others | US$41.94M | US$17.89M | 48.8× | 18.6× | 3.0× | −16.1% | 0.1× | 1.68 |
Team and board
Officers
| Officer | Role |
|---|---|
| James McDonnell | CEO |
| Rebecca Tunstall | Chief Operating Officer |
| Melanie Leydin | Company Secretary |
| Rosalind Wilson | Chief Medical Officer |
| Said Sebti | Scientific Founder |
| Upaly Bahadure | Director – Clinical Affairs & Operations |
Board
| Director | Role |
|---|---|
| James Campbell | Non-Executive Chair |
| Allen Ebens | Non-Executive Director |
| Ellen Feigal | Non-Executive Director |
| Gavin Shepherd | Non-Executive Director |
| Melanie Farris | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Aug 20, 2025 | −2.3% |
| Q2 2025 | Feb 20, 2025 | −2.1% |
| Q2 2023 | Feb 24, 2023 · After close | 0.0% |
| Q4 2022 | Aug 22, 2022 · After close | −2.3% |
| Q2 2022 | Feb 24, 2022 | −3.0% |
| Q4 2021 | Aug 30, 2021 | 0.0% |
| Q2 2021 | Feb 24, 2021 | −9.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (October 2026) | Shareholder meeting | 19 slides | Oct 14, 2026 |
| Investor Presentation (August 2026) | Investor deck | 29 slides | Aug 26, 2026 |
| Investor Presentation (April 2026) | Investor deck | 31 slides | Apr 30, 2026 |
| Shareholder Meeting (October 2025) | Shareholder meeting | 20 slides | Oct 14, 2025 |
| Investor Presentation (July 2025) | Investor deck | 40 slides | Jul 4, 2025 |
| Investor Presentation (May 2025) | Investor deck | 38 slides | May 29, 2025 |
| Investor Presentation (May 2025) | Investor deck | 23 slides | May 21, 2025 |
| Investor Presentation (April 2025) | Investor deck | 24 slides | Apr 17, 2025 |
| Investor Presentation (March 2025) | Investor deck | 33 slides | Mar 31, 2025 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 33 slides | Nov 14, 2024 |
All 45 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of fully paid ordinary shares Closed: A$1.2M raised · A$0.065 a share Use of proceeds: Strengthen cash position and fund continued development of PTX-100 beyond the first Dose Optimisation Committee review | Sep 29, 2026 | US$845,261 |
| Share purchase plan of shares Closed: A$4.8M raised · A$0.065 a share Use of proceeds: Strengthen cash position and fund continued development of PTX-100 beyond the first Dose Optimisation Committee review | Sep 23, 2026 | US$3.38M |
| Share purchase plan of securities under the SPP Terms changed: share purchase plan | Sep 15, 2026 | |
| Share purchase plan of new fully paid ordinary shares Update: up to A$7M · A$0.065 a share · Reach Markets Pty Ltd Dealers: Reach Markets Pty Ltd (lead) Insiders: All eligible directors have participated in the SPP Use of proceeds: Advance PTX-100 beyond the Dose Optimisation Committee meeting expected in December 2026 | Sep 14, 2026 | US$5.04M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.36M | 3.71M | 2.43M | 1.89M | 1.19M | 1.03M | 72.1K | 939.8K | 166.2K | |
| Cost of revenue | 110.3K | 717 | 2.09K | 1.40K | 474 | 904 | 1.34K | 1.47K | 605 | |
| Gross profit | -110.3K | 4.36M | 3.71M | 2.43M | 1.89M | 1.19M | 1.03M | 1.65M | 938.3K | 1.22M |
| Research and development | 5.28M | 6.72M | 6.97M | 6.22M | 3.40M | 2.50M | 2.76M | 3.68M | 2.06M | 2.43M |
| Selling, general and administrative | 5.31M | 1.46M | 1.49M | 1.35M | 1.11M | 961.5K | 1.13M | 1.86M | 929.4K | 1.33M |
| Operating income | -10.6M | -7.54M | -7.19M | -9.89M | -7.10M | -5.43M | -4.49M | -3.79M | -3.61M | -3.76M |
| Depreciation and amortization | 110.3K | 5.30K | 717 | 2.09K | 1.40K | 474 | 904 | 1.34K | 1.47K | 605 |
| EBITDA | -10.5M | -7.53M | -7.19M | -9.88M | -7.10M | -5.43M | -4.49M | -3.79M | -3.60M | -3.76M |
| Interest expense | 10.7K | 6.53K | 10.6K | 4.19K | 3.30K | 2.20K | 0 | |||
| Income before tax | -10.4M | -7.32M | -11.9M | -9.37M | -6.87M | -4.15M | -4.35M | -3.80M | -3.51M | -2.57M |
| Income tax | -3.44M | -4.36M | -3.71M | -2.37M | -1.75M | -1.19M | -1.03M | -1.63M | -940.0K | -1.06M |
| Net income | -7.00M | -7.32M | -8.24M | -7.00M | -5.12M | -4.15M | -3.32M | -3.80M | -2.57M | -2.57M |
| Earnings per share, basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.03M | 6.91M | 10.5M | 5.90M | 12.3M | 16.1M | 7.36M | 9.64M | 5.49M | 7.65M |
| Short-term investments | 20.0K | 20.0K | 4.02M | 16.0M | 20.0K | 20.0K | 20.0K | 20.0K | 20.0K | 20.0K |
| Receivables | 3.70M | 264.3K | 3.92M | 2.58M | 1.72M | 1.24M | 1.06M | 1.75M | 939.2K | 1.06M |
| Inventory | 246.3K | 1 | 1 | 267.7K | 1 | 1 | 1 | |||
| Current assets | 14.0M | 12.9M | 18.7M | 24.7M | 14.2M | 17.6M | 8.71M | 11.6M | 6.62M | 8.86M |
| Property, plant and equipment | 7.40K | 2.10K | 2.82K | 4.90K | 1.88K | 38 | 942 | 2.28K | 2.23K | |
| Total assets | 16.3M | 14.6M | 20.4M | 28.1M | 17.6M | 21.0M | 12.1M | 15.0M | 9.99M | 12.2M |
| Accounts payable | 902.0K | 3.04M | 1.72M | 1.78M | 505.3K | 232.6K | 479.9K | 393.2K | 243.2K | 340.8K |
| Current liabilities | 1.96M | 3.16M | 2.32M | 2.03M | 809.1K | 514.7K | 864.2K | 668.0K | 543.8K | 440.6K |
| Total debt | 223.0K | 330.5K | 165.8K | 156.9K | 156.9K | 56.0K | ||||
| Total liabilities | 2.08M | 3.17M | 2.33M | 2.03M | 856.0K | 539.7K | 884.0K | 685.8K | 551.6K | 444.9K |
| Shareholders' equity | 14.2M | 11.4M | 18.1M | 26.1M | 16.8M | 20.4M | 11.2M | 14.3M | 9.44M | 11.8M |
| Shares outstanding | 1.03B | 805.3M | 805.3M | 727.5M | 647.8M | 611.8M | 394.3M | 244.5M | 215.2M | 213.8M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7.22M | -7.24M | -7.40M | -6.19M | -4.31M | -3.97M | -2.32M | -4.20M | -2.15M | -3.28M |
| Capital spending | 0 | 0 | -3 | 0 | -4.43K | -2.31K | -2.31K | -2.31K | -1.52K | -1.69K |
| Free cash flow | -7.22M | -7.24M | -7.40M | -6.19M | -4.32M | -3.97M | -2.32M | -4.20M | -2.15M | -3.28M |
| Cash from investing | 4.00M | 12.0M | -16.0M | -4.43K | -2.31K | -2.31K | -2.31K | -1.52K | -21.7K | |
| Cash from financing | 9.34M | -330.5K | 18.1K | 15.8M | 428.3K | 12.7M | 12.7M | 8.37M | -635 | 1.22M |
| Dividends paid | -12.7M | -7.67M | -2.47K | |||||||
| Share buybacks | -683.2K | 0 | 18.1K | 16.5M | 594.1K | -836.6K | -836.6K | -699.5K | -1.84K | -134.5K |
| Change in cash | 2.12M | -3.59M | 4.60M | -6.37M | -3.83M | 8.74M | -2.30M | 4.15M | -2.16M | -2.11M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Prescient receives $3.4 million R&D Tax Refund | Nov 11, 2026 | Financing | ASX |
| Notification of cessation of securities - PTX | Nov 8, 2026 | Financing | ASX |
| Change of Company Secretary | Oct 22, 2026 | Management or board change | ASX |
| Results of Annual General Meeting | Oct 14, 2026 | Meeting outcome | ASX |
| Chair Address and CEO AGM Presentation | Oct 13, 2026 | Meeting outcome | ASX |
| September 2026 Quarterly Update and Appendix 4C | Oct 12, 2026 | Quarterly report | ASX |
| Change of Director's Interest Notice | Oct 5, 2026 | Ownership change notice | ASX |
| Change of Director's Interest Notice | Oct 5, 2026 | Ownership change notice | ASX |
| Change of Director's Interest Notice | Oct 5, 2026 | Ownership change notice | ASX |
| Notification regarding unquoted securities - PTX | Sep 29, 2026 | Other filings | ASX |
Show 200 filings
This page holds 200 of 249 filings. Open Filings
Cap table
Built by 6ix from Prescient Therapeutics Limited’s releases · as of Sep 29, 2026
- Common shares
- 1,143,849,969
- Fully diluted
- 1,143,849,969
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,143,849,969 | Sep 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 29, 2026 | 1,143,849,969 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Allen Ebens | Non-Executive Director · Since at least Nov 4, 2026 |
| Ellen Feigal | Non-Executive Director · Since at least Nov 5, 2026 |
| Gavin Shepherd | Non-Executive Director · Since at least Nov 5, 2026 |
| James Campbell | Non-Executive Chair · Since at least Oct 13, 2026 |
| James McDonnell | CEO · Since at least Aug 25, 2026 |
| Melanie Farris | Non-Executive Director · Since at least Nov 5, 2026 |
| Melanie Leydin | Company Secretary · Since at least Nov 5, 2026 |
| Rebecca Tunstall | Chief Operating Officer · Since at least Nov 4, 2026 |
| Rosalind Wilson | Chief Medical Officer · Since at least Nov 4, 2026 |
| Said Sebti | Scientific Founder · Since at least Nov 4, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Upaly Bahadure | Director – Clinical Affairs & Operations · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Prescient Therapeutics Limited.